Balyasny Asset Management L.P. Decreases Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Balyasny Asset Management L.P. trimmed its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 32.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 221,391 shares of the company’s stock after selling 104,043 shares during the quarter. Balyasny Asset Management L.P.’s holdings in Keros Therapeutics were worth $3,505,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Keros Therapeutics by 585.9% during the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company’s stock valued at $3,379,000 after buying an additional 182,314 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Keros Therapeutics during the 4th quarter valued at about $388,000. Darwin Global Management Ltd. raised its position in shares of Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock valued at $26,707,000 after buying an additional 163,403 shares in the last quarter. Barclays PLC raised its position in shares of Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after buying an additional 35,022 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Keros Therapeutics during the 4th quarter valued at about $1,027,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $13.65 on Monday. The company has a market capitalization of $554.39 million, a P/E ratio of -2.62 and a beta of 1.32. The company’s 50-day simple moving average is $12.20 and its two-hundred day simple moving average is $24.23. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.63. The business had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period in the prior year, the firm earned ($1.21) EPS. On average, research analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company’s stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 20.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Scotiabank cut their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday, January 16th. HC Wainwright cut their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. Finally, Wedbush reiterated a “neutral” rating and set a $15.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $38.67.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.